Haleon plc

Equities

HLN

GB00BMX86B70

Pharmaceuticals

Market Closed - London S.E. 16:35:28 20/05/2024 BST 5-day change 1st Jan Change
332 GBX +0.91% Intraday chart for Haleon plc +1.10% +3.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Chart Haleon plc
More charts
Haleon plc specializes in the research, manufacture and marketing of drugs and consumer pharmaceutical products. Net sales break down by family of products as follows: - oral health products (27.7%; no. 1 worldwide): Sensodyne, Parodontax, Polident, Biotene, Aquafresh brands, etc.; - Pain relief medicines (23.5%; no. 1 worldwide): Panadol, Advil, Voltaren, Excedrin brands, etc.; - medicines for digestive health (18.9%; no. 1 worldwide): TUMS, Nicorette, ENO, Chap Stick, Fenistil, Nexium brands, etc.; - respiratory medicines (15.4%; no. 1 worldwide): Theraflu, Otrivin, Flonase, Contac brands, etc.; - vitamins, minerals and food supplements (14.5%; no. 1 worldwide): Centrum, Emergen-C, Caltrate brands, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa/Latin America (40.2%), North America (37.1%), and Asia/Pacific (22.7%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
3.32 GBP
Average target price
3.62 GBP
Spread / Average Target
+9.04%
Consensus
  1. Stock Market
  2. Equities
  3. HLN Stock
  4. News Haleon plc
  5. Barclays Lifts Haleon PT, Maintains Overweight Rating